论文部分内容阅读
目的：观察影像引导下微波消融联合放疗治疗IIA期非小细胞肺癌（Non-Small Cell Lung Cancer，NSCLC ）的临床疗效及其安全性。方法选取我院2009年2月～2015年2月收治的不适宜外科手术或拒绝手术的IIA期NSCLC患者共计36例（36个肿瘤），采用CT引导下冷循环微波消融治疗，消融7 d后序贯放射治疗。治疗前后增强CT观察肿瘤局部坏死率，随访疾病进展时间、生存期，观察治疗中及治疗后的不良事件发生以及处理和转归情况。结果治疗后CT表现为肿瘤消融区可见气化，肺窗可见肿瘤边界模糊呈毛玻璃样改变。36个肿瘤中完全坏死率88.9%（32/36），不完全坏死率11.1%（4/36）。治疗后3、6、12个月随访，肿瘤体积逐渐缩小，平均缩小率为（8.2±6.1）%、（34.1±7.4）%及（52.6±8.3）%。治疗后1、2、3年患者生存率分别为83.3%（30/36）、58.3（21/36）、38.9%（14/36）。术中及术后未出现严重并发症。结论 CT引导下微波消融序贯放射治疗IIA期非小细胞肺癌可获得较好的局部控制效果和较高的3年生存率，适用于不适宜或拒绝接受手术的NSCLC患者。“,”Objective To observe the clinical efifcacy and safety of combination of application of MVA (Micro-Wave Ablation) and image-guided radiotherapy in treatment of Stage IIA NSCLC (Non-Small Cell Cancer) patients.Methods Altogether 36 patients (36 tumors) with Stage IIA NSCLC who were treated in the hospital from February 2009 to February 2015 and unsuitable for or rejected surgical operation were selected and underwent cool-circulation MVA under the guidance of CT. And then, they accepted sequential radiotherapy 7 days after ablation treatment. Strengthened CT was used to observe the preoperative and postoperative local necrosis rate of tumors. Additionally, the disease progression time and survival time were followed up; and the incidence of intraoperative and postoperative adverse events and treatment and prognosis were also observed.Results The postoperative CT ifndings included visible gasiifcation in the ablation area as well as the blurred tumor boundary and glass-like changes in the lung window. Among 36 tumors, the complete necrosis rate was 88.9% (32/36);the incomplete necrosis rate was 11.1% (4/36). After 3, 6 and 12-months followed-up, the tumor size was gradually reduced and the average reduction rate was (8.2±6.1)%, (34.1±7.4)% and (52.6±8.3)%. The postoperative survival rates in 1, 2 and 3 years were 83.3% (30/36), 58.3 (21/36) and 38.9% (14/36) respectively. There were no serious intraoperative and postoperative complications.Conclusion CT-guided MVA combined with radiotherapy demonstrated its good local control effect and a high 3-year survival rate in the treatment of Stage IIA NSCLC, which suited the patients who were unsuitable for or rejected surgical operation .